Using murine models, we have previously demonstrated that recombinant adeno-associated virus (rAAV)-mediated microdystrophin gene transfer is a promising approach to treatment of Duchenne muscular dystrophy (DMD). To examine further therapeutic effects and the safety issue of rAAV-mediated microdystrophin gene transfer using larger animal models, such as dystrophic dog models, we first investigated transduction efficiency of rAAV in wild-type canine muscle cells, and found that rAAV2 encoding b-galactosidase effectively transduces canine primary myotubes in vitro. Subsequent rAAV2 transfer into skeletal muscles of normal dogs, however, resulted in low and transient expression of b-galactosidase together with intense cellular infiltrations in vivo, where cellular and humoral immune responses were remarkably activated.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked, lethal disorder of skeletal muscle caused by mutations in the dystrophin gene, which encodes a large subsarcolemmal cytoskeletal protein, dystrophin. DMD is characterized by a high incidence (one among 3500 boys) and a high frequency of de novo mutation. 1 The absence of dystrophin accompanies the loss of dystrophinassociated glycoprotein complex from the sarcolemma and results in progressive muscle weakness, cardiomyopathy and early death. Although several treatment modalities, such as gene, cell and pharmacological therapies, have been researched to aim at correcting the dystrophic phenotypes, DMD currently has no effective treatment.
An adeno-associated virus (AAV) vector is a potential tool for gene therapy of inherited neuromuscular disorders. It is a nonpathogenic, low immunogenic and replication-defective viral vector that effectively infect nondividing cells, such as skeletal muscle fibers. 2 The size of exogenous DNA fragment which can be inserted into recombinant AAV vectors (rAAVs), however, is limited to up to 4.9 kb. Therefore, full-length dystrophin (14 kb) and mini-dystrophin (6.4 kb) cDNAs are too large to be incorporated into a rAAV. We and others have tried to design a short but functional microdystrophin gene that could be utilized as the therapeutic tool for DMD. [3] [4] [5] [6] We constructed a series of rod-truncated microdystrophin cDNAs, 3 and generated transgenic mdx mice expressing each microdystrophin, and demonstrated that microdystrophin CS1 with four rod repeats and three hinges was a good candidate for therapeutic molecule. 7 We have also showed that the muscle-specific muscle creatine kinase (MCK) promoter in a rAAV drives longer transgene expression than the ubiquitous cytomegalovirus (CMV) promoter in mdx muscle. 8 Therefore, we generated the rAAV2 expressing microdystrophin DCS1 (3.8 kb cDNA) driven by the MCK promoter and introduced it into mdx muscles, and showed that sustained expression of microdystrophin from rAAV significantly ameliorates dystrophic phenotypes of treated mdx mice. 9 These results indicate that rAAVmediated microdystrophin transfer is a good therapeutic strategy for dystrophin deficiency.
For the application of our strategy to DMD patients, it is necessary to examine the therapeutic effects and the safety issue in larger animal models. To this end, we have recently established a colony of beagle-based canine X-linked muscular dystrophy in Japan (CXMD J ). 10, 11 In contrast to moderate dystrophic changes of mdx mice, CXMD J show similar dystrophic phenotypes to those of human DMD: increased serum creatine kinase level, gross muscle atrophy with joint contractures, cardiomyopathy, prominent muscle necrosis, degeneration with mineralization and concurrent regeneration, and endomysial and perimysial fibrosis. 11, 12 Therefore, affected dogs are useful for preclinical trials to predict the clinical effectiveness in DMD application. In addition, side effects of treatment modalities should be investigated in detail in the dog model to avoid unexpected, detrimental effects on DMD patients. For instance, human trial in hemophilia B was ineffective due to T-cell-mediated immunity to AAV capsid antigens, and represented the matter that further studies for immunomodulation in preclinical and human trials were required to achieve successful transduction. 13 In this report, we demonstrate that rAAV2 efficiently infect canine myotubes and express the lacZ gene in vitro. In contrast, rAAV-mediated gene transfer into canine muscle in vivo elicits severe immune responses against the gene product, due to susceptive immune responses in the dog. These results suggest that it is important to know molecular backgrounds of immune response against AAV particles and its gene product in the host and consider immunosuppression in preclinical and clinical settings.
Results

rAAV2-CMVLacZ efficiently transduces canine primary myotubes in vitro
To investigate the transduction efficiency of a rAAV2 in canine muscle cells, we first infected primary myotubes prepared from C57BL/6 mice and wild-type beagle with rAAV type 2 encoding b-galactosidase (b-gal) driven by the CMV promoter (rAAV2-CMVLacZ) at doses from 2 Â 10 8 to 2 Â 10 11 vector genomes (vg) (Figure 1) . Surprisingly, more canine myotubes were b-gal-positive than murine ones. To enhance the transgene expression by converting single-strand viral DNAs into doublestrand DNAs after the rAAV infection, 14 we next coinfected myotubes with helper adenovirus (Ad) and rAAV2. As expected, Ad enhanced the expression of lacZ in both murine and canine myotubes, but b-gal expression was much more robust in canine primary myotubes than in mouse primary myotubes. Transfer of rAAV into canine skeletal muscle K Yuasa et al
Low efficacy of gene transfer via rAAV into canine skeletal muscle in vivo
To examine the transduction efficiency of rAAV2 in canine myofibers in vivo, rAAV2-CMVLacZ was injected into skeletal muscles of wild-type beagles and golden retrievers at various ages, and b-gal expression in the rAAV-injected muscles were evaluated at 2, 4 and 8 weeks after the injection (Figure 2a and Table 1 ). We previously reported that intramuscular injection of the rAAV2 into normal mice permitted sustained b-gal expression for at least 8 weeks. 8 In contrast to the mice, however, a few b-gal-positive fibers were observed in canine muscles at 2, 4 and 8 weeks after the injection of rAAV2-CMVLacZ both in beagles and golden retrievers. Moreover, in the rAAV2-injected canine muscles, a large number of mononuclear cells were observed around b-gal-expressing fibers at 2, 4 and 8 weeks after the injection (hematoxylin and eosin (H&E) in Figure 2a , Table 1 ). rAAV injection at neonatal stage or administration of low dose of the rAAV resulted in a little prolonged Figure 2 Low transgene expression and marked cellular infiltration after rAAV2-mediated gene transfer into canine skeletal muscle. rAAV2-CMVLacZ was injected into normal muscles of beagles or golden retrievers at various ages. (a) Representative images of b-gal expression and histological change in the rAAV-injected murine (TA) and canine muscles at 2, 4 and 8 weeks post-injection (left TA, right TA and right ECU muscles of dog FD89 in Table 1 , respectively). The same batches of rAAV2-CMVLacZ were injected into murine and canine skeletal muscles. Identical parts of the serial cross-sections were shown in X-Gal and H&E stains. Large and widespread (2w), or scattered clusters (4w, 8w) of infiltrating cells were observed in the rAAV-injected canine muscles. (Table 1 , dogs 3290, 7690 and 901). To determine whether contamination of cellular proteins in the stocks of AAV vectors lowers transduction efficiency, we tried three different AAV preparation protocols: (i) two-cycle CsCl density gradient ultracentrifugation, (ii) heparin column chromatography, or (iii) combination of them, and found that preparation using heparin column chromatography showed high levels of contamination of transgene products and cellular proteins (Supplementary Figure 1) . CsCl ultracentrifugation efficiently eliminated contaminated empty viral particles. Combination of these two methods almost completely eliminated contaminated proteins. Nevertheless, all rAAV stocks showed high levels of b-gal expression in murine muscles (data not shown), but evoked cellular infiltration in normal canine muscles (Supplementary Figure 1) .
To quantify the levels of infection and transduction of rAAV2-CMVLacZ in canine muscles, we isolated DNA and RNA from the injected muscles, and semiquantitatively evaluated rAAV genome copy numbers and the level of b-gal mRNA by PCR and reverse transcription (RT)-PCR, respectively. AAV vector genomes and b-gal mRNA were detected at 2, 4 and 8 weeks after the injection (Figures 2b and c) . b-Gal protein, however, could not be detected by western blot at all stages after the injection (Figure 2d ). These results suggest that canine myofibers were transduced by a rAAV2 in vivo, but the transduced cells were eliminated by the host's defense mechanisms.
rAAV-mediated gene transfer into canine muscles evoke both cellular and humoral immune response
We next analyzed cell markers on infiltrating cells in the rAAV2-CMVLacZ-injected muscles ( Figure 3a ) at 2 weeks after the injection at 12 weeks. Numerous CD4+ or CD8+ T lymphocytes were detected in the interstitial spaces of the injected muscle. CD11b+ cells and B cells were also detected in the cluster of infiltrating cells. Furthermore, the expression of the major histocompatibility complex (MHC) class I and -II molecules were highly upregulated on both mononuclear cells and muscle fibers. IgG deposits were found in both the Transfer of rAAV into canine skeletal muscle K Yuasa et al cytoplasm of myofibers and the extracellular space in the rAAV-injected muscle. We next examined the antibodies against the transgene product or rAAV particles in the sera of rAAV-injected dogs ( Figure 3b ). The levels of serum IgGs that react b-gal protein or rAAV2 particle were gradually increased with time in both 2-day-old and 8-week-old injections. When injected at 8 weeks, the levels of IgGs against b-gal or rAAV2 increased from 2 weeks after the injection, and reached the peak at 4 weeks. When injected at 2 days, anti-b-gal or anti-AAV antibodies were not detected at 2 weeks after the injection, but had begun to increase at 4 weeks. The results would explain why the lacZ was expressed for a longer time, when injected at neonatal age (Table 1) . These results suggest that cellular and humoral immune responses are elicited after the transfer of a rAAV2 into canine muscles.
Administration of a rAAV expressing no transgene into canine muscles
Transduction of skeletal muscle by rAAV2-CMVLacZ presents two main foreign antigens, namely b-gal protein and AAV capsid to the host's immune system. To test which antigen is responsible for rapid elimination of transduced myofibers after rAAV-mediated gene transfer into canine muscle, we constructed a rAAV2 expressing no transgene, named rAAV2-LacZ-P(À), by removing the MCK promoter from the parental rAAV2-MCKLacZ ( Figure 4a ). We confirmed that the promoter-deleted rAAV2 expressed no b-gal in muscle after injection into skeletal muscles of normal mice (5 Â 10 11 vg/50 ml/site) (data not shown). Then, we injected the same titers of rAAV2-LacZ-P(À) and rAAV2-CMVLacZ, into skeletal muscles of normal adult beagles, and evaluated transduction efficiency by quantitative PCR of AAV genomes or histopathologically at 2 and 4 weeks post-injection. In 5 Â 5 Â 10 mm tissues of rAAV2-LacZ-P(À)-injected muscles, 1-10 pg of rAAV genomes were detected by PCR, whereas 500 fg to 5 pg of rAAV sequences were amplified in the injected muscles of rAAV2-CMVLacZ (Figures 2b  and 4b ). These results indicate that the promoter-deleted rAAV2 could successfully infect canine muscles and the viral genomes were retained stably in the fibers.
H&E staining showed that deletion of the MCK promoter greatly reduced the cellular infiltration into the rAAV2-LacZ-P(À)-injected muscles at 2 and 4 weeks after the injection, in contrast to the rAAV2-CMVLacZinjected muscles (Figure 4 ). Even in a muscle sample in which vector genome was detected at the highest level by PCR, infiltrating cells were rarely found (sample 1c in Figures 4b and c) . In addition, CD4+ or CD8+ cells were not detected in the rAAV2-LacZ-P(À)-injected muscles (data not shown). These results suggest that the transgene product but not AAV particle strongly elicits immune responses that subsequently eliminated transduced myofibers. (b) Humoral immune responses against the transgene product and rAAV particle in the rAAV-treated dogs. Sera from dogs injected with rAAV2-CMVLacZ at 2 days and 8 weeks were analyzed for the presence of IgG antibodies against b-gal or AAV particle at 0, 2, 4 and 8 weeks after the injection, using ELISA. Dogs: 9223 and 0338. AAV, adeno-associated virus; b-gal, b-galactosidase; ELISA, enzyme-linked immunosorbent assay; MHC, major histocompatibility complex; rAAV, recombinant adeno-associated virus; TA, tibialis anterior.
Transfer of rAAV into canine skeletal muscle K Yuasa et al Figure 4 Injection of the promoter-deleted rAAV2 showed negligible cellular infiltration in canine muscle. The promoter-deleted rAAV2, rAAV2-LacZ-P(À) (5 Â 10 12 vg/500 ml/site) was injected into skeletal muscles of 10-week-old beagle (dog 902), and the injected muscles and sera were analyzed at 2 and 4 weeks post-injection. (a) Schematic illustration of rAAV2-LacZ-P(À). Upper and lower bars correspond to primer positions used for detection of genome in Figure 4b . (b) Detection of rAAV genome DNA in the rAAV-LacZ-P(-)-injected canine muscles. Total DNA was extracted from the muscle sections, and LacZ DNA fragment (275 bp) was amplified from 200 ng of template DNA by PCR. Results at 2 weeks after the injection were shown. The numbers 1a-2c show individual identities of the muscle specimen divided into pieces. Vector genomes were detected in all samples, but amplified levels were different between muscle blocks. STD: quantity standard of AAV vector plasmid; rAAV-P(À): rAAV2-LacZ-P(À) genome. (c) Cellular infiltrations were rarely observed in the rAAV2-LacZ-P(À)-injected canine TA muscle (sample 1c). Canine muscles were injected with the rAAVs expressing b-gal or no transgene, and the muscle blocks were sectioned and stained with H&E staining at 2 weeks after the injection. All muscle samples from rAAV2-CMVLacZ (1a-2c) showed minimal cellular infiltration. Magnification: Â 200. (d) Detection of antibodies against AAV particles and b-gal in the rAAV-treated dogs. Sera from dogs injected with rAAV2-LacZ-P(À) (dog 902) or rAAV2-CMVLacZ (dogs 0338, 901 and FF04, also see Table 1 ) were analyzed by using the ELISA technique for the presence of IgG antibodies against AAV particles and b-gal protein at 0, 2 and 4 weeks after the injection. AAV, adeno-associated virus; b-gal, b-galactosidase; ELISA, enzyme-linked immunosorbent assay; rAAV, recombinant AAV.
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Next, we measured the anti-AAV IgG type antibodies in the serum of the treated dogs (Figure 4d ). In the rAAV2-LacZ-P(À)-injected dog at 2 and 4 weeks after the injection, anti-AAV2 antibodies were detected at high levels similar to those in rAAV2-CMVLacZ-injected dogs, but antibodies against b-gal were undetectable. This indicates that antibodies against AAV particles were developed in rAAV2-LacZ-P(À)-injected dogs but did not lead to elimination of transduced cells.
Immunosuppression of the rAAV-injected dogs slightly improved the expression of the transgene
To test whether immunosuppression could improve transduction by rAAV-2 in canine muscle, we daily administered cyclosporine to the rAAV2-CMVLacZinjected dogs from À5 day of the injection until the sampling day of muscle specimens (Table 2A) . Unexpectedly, b-gal expression in the injected muscles of cyclosporine-treated dogs was as low as that in the untreated dogs. Only the extensor digitorum longus (EDL) muscle of dog 403 expressed b-gal at a high level at 2 weeks after the injection, although a large number of infiltrating cells with CD4+ or CD8+ cells and upregulation of MHC class I and -II were detected (data not shown). In contrast, in the rAAV2-CMVLacZ-injected extensor carpi ulnaris (ECU) muscle of dog 403 at 2 weeks post-injection, b-gal expression was much lower than that in the EDL muscle. Thus, as a whole, cyclosporine alone could not effectively improve transduction of rAAV2-CMVLacZ.
Mycophenolate mofetil (MMF) suppresses the functions of T lymphocytes in a different way with cyclosporine. Therefore, to suppress immune responses more effectively, we treated the rAAV2-CMVLacZ-injected dogs both with MMF and cyclosporine. MMF was daily administrated from 0 day to the day of sampling ( Figure 5 and Table 2B ). This combined immunosuppression significantly increased the numbers of b-gal-expressing fibers, compared with those in the untreated muscles when examined at 2 weeks after the injection, but cellular infiltration was still observed. Some CD4+ or CD8+ cells and upregulation of MHC class I and -II in infiltrating cells and myofibers were detected in rAAV2-CMVLacZinjected muscle (data not shown). After 4 weeks, b-gal expression significantly decreased together with increasing infiltrating cells. These results indicated that combination of cyclosporine and MMF could partially improve the transduction efficiency of a rAAV2 in canine muscles.
Immunological background of enhanced immune responses in dogs
We next investigated possible differences in immune responses between mice and dogs, which might explain why rAAV2 injection evoked strong immune responses in canine muscles. To this end, we prepared single-cell suspension from spleens of untreated dogs or mice, stimulated them with AAV capsids and purified b-gal protein in vitro, and assayed the secretion of interferon-g (IFN-g) by enzyme-linked immunosorbent assay (ELISA; Table 3 ). We also stimulated the splenocytes with two major mitogens for T lymphocytes, concanavalin A (ConA) and phytohemagglutinin (PHA). When stimulated with ConA or PHA, canine splenocytes secreted much larger amount of IFN-g into the culture medium than murine cells. Furthermore, canine cells secreted slightly higher levels of IFN-g in response to b-gal or rAAV2 capsid proteins than murine cells. These results suggest that canine splenocytes are innately more susceptive to , individual results of the injected muscles were shown.
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Discussion
rAAV2 drives a long-term expression of microdystrophin genes in skeletal muscles of dystrophic mice, 9 therefore it is an attractive tool for treatment of DMD. To test the efficacy and safety of rAAV-mediated gene transfer into skeletal muscle of larger animal models, we directly injected rAAV2 encoding b-gal into skeletal muscle of normal dogs and examined the b-gal expression at several time points. Unexpectedly, we found that rAAV2-mediated gene transfer elicits strong immune responses against the transgene product in canine skeletal muscles. The mechanisms of enhanced immune reactions after rAAV2 injection seen in normal dogs need to be clarified before applying rAAV-mediated gene therapy to boys with DMD.
rAAV2 efficiently transduces canine muscle in vitro but not in vivo
In mice, b-gal expression is maintained for a long time after rAAV-CMVLacZ injection into muscle. 8 In contrast, low levels of b-gal expression and numerous infiltrating cells were observed in the rAAV2-CMVLacZ-injected canine muscle. Surprisingly, rAAV2 infected and transduced canine myotubes more effectively than murine myotubes in vitro (Figure 1 ). Therefore, we conclude that the low expression of the transgene in dog muscle is not due to the lack of receptors for the AAV2 on canine muscle fibers.
Cytotoxic immune response against the transgene product
Immunosuppression reduced cellular infiltration in rAAV2-CMVLacZ-injected muscle and partially rescued the b-gal expression in myofibers, suggesting that cytotoxic T-cell responses to transduced muscle fibers are largely responsible for the elimination of b-galpositive myofibers in the injected muscle. Furthermore, intramuscular injection of the promoter-deleted rAAV2, which can infect the muscle (Figure 4 ) but express no b-gal (data not shown), induced much less cellular infiltration in canine muscle than the rAAV2-CMVLacZ. This observation suggests that massive destruction of the transduced muscle cells is mainly due to cellular immunity against the transgene product but not against AAV capsid proteins. Table 2 ). The rAAV (5.0 Â 10 11 -7.7 Â 10 12 vg/site) was injected into TA and ECU muscles of beagles, and the dogs were daily treated with cyclosporine alone (a) or combination of cyclosporine and MMF (b). The muscle of dog 1102 was injected with rAAV at a dose of 6.0 Â 10 11 vg (upper panels in a). Dog 403 was injected with rAAV at a titer of 7.7 Â 10 12 vg; beagle VC1XE was injected with rAAV at a dose of 5.0 Â 10 11 vg (upper panels in b). TC2XE was injected with 5.0 Â 10 12 vg rAAV (lower panels in b). Magnification: Â 100. ECU, extensor carpi ulnaris; H&E, hematoxylin and eosin; MMF, mycophenolate mofetil; rAAV, recombinant adenoassociated virus; TA, tibialis anterior; X-gal, 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside.
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There have been several papers reporting studies of rAAV-based gene transfer into canine skeletal muscle. Most of them were gene transfer studies for hemophilia B dogs, and reported that cellular immune responses against Factor IX, were nearly absent in dog models of hemophilia B. [15] [16] [17] [18] [19] The difference between studies of hemophilia and ours might be explained by the antigenicity of the transgene products. When we injected rAAV2-CMVM3 expressing M3 microdystrophin 7 into skeletal muscles of normal dogs, cellular infiltration was considerably reduced (data not shown), indicating that lowering the immunogenicity of therapeutic genes is important to improve the efficiency of gene therapy. In addition, nonsecreted, intracellular proteins might tend to evoke cellular immunity, compared with secreted proteins, like Factor IX.
We showed quite low expression of b-gal in rAAV2-CMVLacZ-injected muscle, whereas AAV genome and LacZ mRNA in rAAV-CMVLacZ-injected muscle were detected even at 8 weeks after the injection (Figure 2) . The gap between LacZ mRNA level and b-gal protein cannot be fully explained at present. This might be simply due to time lag between transcription and translation of the transgene, or translation of b-gal might be repressed in inflammatory muscles.
Immunity against AAV2 capsid in dogs and humans
Promoter-deleted rAAV2 injection did develop antibodies against the AAV2 capsid after the injection into the skeletal muscle (Figure 4d ), but did not evoke strong immune reactions in muscle, suggesting that cytotoxic T cells targeting the AAV2 capsid protein were not or minimally activated. This observation is consistent with the previous reports that cellular immune response to the AAV capsid was absent in hemophilia B dogs. [17] [18] [19] However, it is still unclear whether cellular immune response against the AAV2 capsid proteins is completely absent in dogs. Because even a low-level response could be problematic in the clinic, immunity to the AAV2 capsid proteins should be carefully monitored in dog models. In contrast, it has been recently reported that liver-directed rAAV2 transfer for human trial of hemophilia B led to destruction of transduced hepatocytes by cell-mediated immunity targeting the AAV2 capsid. 13 The authors suggest that T-cell immunity against the AAV2 particles might be associated with peptide sequence within the AAV2 capsid which had a high predicted binding potential to B*0702 molecule of human MHC class I. This may explain why cell-mediated immune response against the AAV2 capsid protein was activated in humans.
Backgrounds of immune responses in dogs and mice
We measured the levels of IFN-g secreted from canine or murine splenocytes after stimulation with b-gal, rAAV2 viral particles, ConA or PHA in vitro. Although biological activities (e.g., EC 50 ) of canine IFN-g might be different from those of murine IFN-g, it is likely that canine immune system is more sensitive to foreign antigens, such as b-gal. We also showed that canine splenocytes secrete much larger quantity of INF-g than murine splenocytes when exposed to ConA or PHA. The higher levels of overall immune activation in dogs than in mice might be responsible for rapid development of immune response to rAAV2-mediated gene transfer into canine skeletal muscle, and might be partly explained by the different sanitary status of murine and canine colonies.
Antigen-presenting cells (APCs) in skeletal muscle play an important role in development of immunity to transgene products. 8, 20 Therefore, it is also possible that rAAV transduces APCs more efficiently in dogs than in mice.
Threshold hypothesis for detrimental immune reaction
A previous study showed that systemic delivery of rAAVs, such as isolated limb perfusion (ILP) elicited less immune response than local injection. 19 Other study in hemophilia B dogs suggested that local Factor IX antigen dose in rAAV-injected muscles would be a critical parameter for risk of developing neutralizing antibody in dog. 18 The authors discussed that vector dose of 2 Â 10 12 vg/site and 8.5 Â 10 12 vg/kg might represent a threshold at which an inhibitory anti-Factor IX was or was not induced. These observations might indicate that the local concentration of the rAAV particles and its gene product is an important factor for establishment of immunity against rAAVs. Direct injection of rAAV2-CMVLacZ particles into muscle might cause the excessive expression of b-gal within a small area, and thereby mount strong cellular immune responses against gene products. Recently, we observed that pseudo-typed rAAV2/8 efficiently delivered the transgene into canine muscle (Ohshima et al., unpublished observation). The expression of b-gal from rAAV8-CMVLacZ distributed more widely, and more evenly within the muscle than rAAV2-CMVLacZ after direct injection into canine Transfer of rAAV into canine skeletal muscle K Yuasa et al muscle. We hypothesize that widespread transduction of myofibers at a low dose of a rAAV2/8 could escape the establishment of immunity against the transgene products. New serotypes of AAVs, such as AAV8 or AAV9 can deliver the transgene into musculature of the whole body via circulation. 21, 22 These vectors might overcome the immunological problems that we encountered in rAAV2-mdiated gene transfer into canine muscles.
In conclusion, we found that intramuscular administration of rAAV2-CMVLacZ elicited rapid and severe immune responses against the transgene product in wild-type dogs. This has not been observed in mice. It is important to understand well the mechanisms of immune reactions observed in dogs to circumvent immunological limitations, which might stand in our way in preclinical and clinical trials for DMD.
Materials and methods
Construction and production of rAAVs
We used rAAV2-CMVLacZ and rAAV2-CMVM3, which harbors the LacZ gene or microdystrophin M3 driven by the CMV promoter, respectively. 3, 7, 8 To improve the expression efficiency of the LacZ gene in rAAV2-CMVLacZ, a chimeric intron (human b-globin splicing donor and immunoglobulin splicing acceptor, Promega, Madison, WI, USA) is inserted between CMV promoter and the LacZ gene.
8 rAAV2-LacZ-P(À) was generated by deleting the truncated MCK promoter (358 bp) from rAAV2-MCKLacZ, leaving the MCK enhancer intact. 8 We confirmed that rAAV2-LacZ-P(À) could not express b-gal in murine muscle cells both in vitro and in vivo (data not shown). The rAAV was produced by a plasmid triplecotransfection method, 23 purified by two CsCl density gradient centrifugations 24 and/or heparin column chromatography, 25 and titrated by a quantitative DNA dotblot assay.
Administration of rAAVs into canine or murine skeletal muscles and isolation of the injected muscles Experimental dogs were wild-type littermates of beaglebased CXMD J breeding colony at National Center of Neurology and Psychiatry (NCNP; Tokyo, Japan), 10, 11 or golden retriever muscular dystrophy colony at Murdoch University (Perth, Australia). 26 All animals were cared and treated in accordance with the guidelines approved by Ethics Committee for Treatment of Laboratory Animals at NCNP or Animal Ethics Committee at Murdoch University, where three fundamental principles (replacement, reduction and refinement) were also considered. When a rAAV was injected into dogs, the animals were not vaccinated to relive influences of immune response by vaccination. rAAVs were injected intramuscularly at ages from 2 days to 14 months, and the muscles were isolated after 2, 4 and 8 weeks. Surgeries were done under anesthesia with isoflurane, as described previously. 27 Briefly, the ECU, tibialis anterior (TA) or EDL muscles were surgically exposed and two marker sutures were placed on the mid-belly of the muscle at proximal and distal positions apart approximately 20 mm. rAAV (5 Â 10 10 -8 Â 10 12 vg in 100 or 500 ml) or phosphate-buffered saline (PBS) was injected slowly into the muscles between two markers along the length. In biopsy and necropsy, the entire muscle blocks with two sutures were removed, divided into some pieces, and immediately frozen in isopentane precooled with liquid nitrogen. rAAV (5 Â 10 11 vg/50 ml) was also injected into TA muscles of C57BL/10 mice at 5 weeks, and the muscles were isolated at 2 or 4 weeks after the injection.
Immunosuppression
To suppress immune reaction, we treated rAAV-injected dogs with cyclosporine alone or cyclosporine combined with MMF for immunosuppression. Cyclosporine (NEORAL capsules; Novartis, Basel, Switzerland) was administrated orally at doses of 20-50 mg/kg/day and daily from À5 day of the injection. MMF (CellCept capsules, Roche Pharmaceuticals, Nutley, NJ, USA) was administrated orally at a dose of 30 mg/kg/day and daily from 0 day of the injection.
Histological and immunohistochemical analysis
Transverse cryosections from the rAAV-injected muscles were stained with H&E or 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal). 8 Immunohistochemistry was performed as described previously. 8 Cryosections were incubated with the following antibodies: mouse monoclonal antibodies against canine CD4 (CA13.1E4, Serotec, Oxford, UK), canine CD8a (CA9.JD3, Serotec), canine CD11b (CA16.3E10, Serotec), canine B cells (CA2.1D6, Serotec), class I major histocompatibility antigen (H58A, VMRD, Pullman, WA, USA) and canine MHC class II (CA2.1C12, Serotec), and fluorescein-conjugated goat affinity-purified antibody to dog IgG (whole molecule) (Cappel, Solon, OH, USA). The primary antibodies were detected using VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA, USA), then visualized with diaminobenzidine, and counterstained with methyl green.
In vitro infection assay in primary myotubes
Canine or murine primary myoblasts were isolated and differentiated into myotubes, according to the previously published protocol 28 with some modifications. Briefly, muscle mass was removed from dogs or mice at 0 day to 2 weeks, weighted and minced. Cells were enzymatically dissociated in PBS (4 ml per g of tissue) containing dispase II (2.4 IU/ml, Godo Shusei, Tokyo, Japan) and Collagenase type XI (0.2%, Sigma, St Louis, USA), and 2.5 mM CaCl 2 . The slurry was incubated at 371C for 90-120 min with trituration every 15 min, and then passed through 100 mm pore mesh. The filtrate was spun at 350 g, and the pellet was resuspended in growth medium (F-10 medium with 20% fetal bovine serum (FBS) and 2.5 ng/ml human basic fibroblast growth factor (Sigma)). The cell suspension was then plated on non-coated dishes for 90 min, and non-adherent cells were collected and plated onto new dishes. After several repeats of this pre-plating procedure, myoblasts were enriched. To assess transduction efficiency of a rAAV in primary myotubes, the same numbers of myoblasts (2 Â 10 4 cells/ well) were plated onto 24-well plates and maintained for a few days in differentiation medium (Dulbecco's modified Eagle's medium with 5% FBS and 10 mg/ml human insulin (Sigma)), and then cultured in the presence of rAAV2-CMVLacZ (2 Â 10 8 -2 Â 10 11 vg/well), or co-infected with the rAAV2 and adenovirus Ad5-dlX 3 Transfer of rAAV into canine skeletal muscle K Yuasa et al
(1 Â 10 7 plaque-forming unit (PFU)/ml). After 2 days, cells were stained with X-Gal.
Quantification of rAAV genome in canine muscle
To quantify rAAV genomes, muscle sections were digested with proteinase K, followed by phenol/chloroform extraction and isopropanol precipitation. The DNA pellet was resuspended in TE buffer, and amplified by PCR with following primer sets: 5 0 -ccacgctgttttgacctccatag-3 0 (downstream of transcription start site in the CMV promoter) and 5 0 -gtacaattccgcagcttttagagc-3 0 (upstream of the LacZ gene) for rAAV2-CMVLacZ (the PCR product is 244 bp, illustrated in Figure 1a) ; 5 0 -gcagttatctggaagat cagg-3 0 and 5 0 -cataaccaccacgctcatcg-3 0 (within the LacZ gene) for rAAV2-LacZ-P(À) (the PCR product is 275 bp, illustrated in Figure 4a ). As an internal control, the canine calmodulin gene II (CaMII; GenBank accession no. D12622) was amplified with following primers: 5 0 -gagaggactcatccaaggtcacac-3 0 and 5 0 -tcagaaaccacggcat cagg-3 0 . AAV vector plasmids for rAAV2-CMVLacZ or rAAV2-LacZ-P(À) were served as a quantity control for standard amplification.
RT-PCR for transgene mRNAs
Total RNA was isolated from muscle sections using RNAqueous-Micro kit (Ambion, TX, USA). Then firststrand cDNA was synthesized using First-Strand cDNA Synthesis Kit (GE Healthcare UK Ltd, Buckinghamshire, UK). mRNA of rAAV2-CMVLacZ was detected using the same primers used for genomic DNA (Figure 1a) . The amplified product is 178 bp. As an internal control glyceraldehyde-3-phosphate dehydrogenase mRNA (GenBank accession no. AB038240) was amplified using the following primer set: 5 0 -tcatctctgctccttctgctgat-3 0 and 5 0 -ggctagaggagccaagcagtt-3 0 .
Western blot analysis
Muscle extracts were prepared from rAAV-injected canine muscles, separated on 7.5% sodium dodecyl sulfate-polyacrylamide gels, and then transferred onto polyvinylidene fluoride membranes, as described previously. 8 b-Gal protein was detected by rabbit polyclonal anti-b-gal antibody (Cappel).
ELISA ELISA were performed as described previously. 8 The microtiter plate was precoated with b-gal, rAAV2-CMVLacZ or rAAV2-LacZ-P(À), incubated with the sera from dogs, and then reacted with a 1/5000 dilution of peroxidase-conjugated rabbit anti-dog IgG (whole molecule) (Sigma). Reactivity was determined by the color reaction of 3,3 
IFN-g release assay
Spleen cells were isolated from C57BL/6 mice or beagle dogs, which were untreated with rAAVs. Splenetic cells were dissociated physically and passed through 100 mm filters. After removal of red blood cells using 0.83% ammonium chloride buffer (Sigma), splenocytes were cultured in RPMI medium containing 10% FBS at a density of 2 Â 10 6 cells/well in 24-well plates for 2 days in the presence of various antigens: b-gal (500 ng to 50 mg), rAAV2-CMVLacZ (1 Â 10 8 -1 Â 10 10 vg), ConA (5 ng to 5 mg, GE Healthcare Bio-Science) and phytohemagglutinin (50 ng to 50 mg, Sigma). The supernatant of the culture was assayed for the secretion of IFN-g using Mouse or Canine IFN-g Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA). The amounts of canine or murine IFN-g were calibrated using recombinant canine or murine IFN-g proteins as standards, respectively, according to manufacturer's instructions. Results are given as means with standard deviation (s.d.) of three experiments. Data were first evaluated by F-test. When equality of variances was shown, t-test was used to evaluate the statistical significance. When rejected, Aspin-Welch-test was used.
